These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29409840)

  • 1. Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions.
    Daniels AL; Randolph TW
    J Pharm Sci; 2018 May; 107(5):1313-1321. PubMed ID: 29409840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microflow Imaging Analyses Reflect Mechanisms of Aggregate Formation: Comparing Protein Particle Data Sets Using the Kullback-Leibler Divergence.
    Maddux NR; Daniels AL; Randolph TW
    J Pharm Sci; 2017 May; 106(5):1239-1248. PubMed ID: 28159641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events.
    Kotarek J; Stuart C; De Paoli SH; Simak J; Lin TL; Gao Y; Ovanesov M; Liang Y; Scott D; Brown J; Bai Y; Metcalfe DD; Marszal E; Ragheb JA
    J Pharm Sci; 2016 Mar; 105(3):1023-7. PubMed ID: 26886324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
    Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
    Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep Convolutional Neural Network Analysis of Flow Imaging Microscopy Data to Classify Subvisible Particles in Protein Formulations.
    Calderon CP; Daniels AL; Randolph TW
    J Pharm Sci; 2018 Apr; 107(4):999-1008. PubMed ID: 29269269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing Precision Limits of Neural Network-Based Quality Control Metrics in High-Throughput Digital Microscopy.
    Calderon CP; Ripple DC; Srinivasan C; Ma Y; Carrier MJ; Randolph TW; O'Connor TF
    Pharm Res; 2022 Feb; 39(2):263-279. PubMed ID: 35080706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable Threshold Method for Determining the Boundaries of Imaged Subvisible Particles.
    Cavicchi RE; Collett C; Telikepalli S; Hu Z; Carrier M; Ripple DC
    J Pharm Sci; 2017 Jun; 106(6):1499-1507. PubMed ID: 28209364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.
    Zhou C; Qi W; Lewis EN; Randolph TW; Carpenter JF
    J Pharm Sci; 2016 Aug; 105(8):2302-9. PubMed ID: 27290624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Closing the Gap: Counting and Sizing of Particles Across Submicron Range by Flow Cytometry in Therapeutic Protein Products.
    Zhang L; Shi S; Antochshuk V
    J Pharm Sci; 2017 Nov; 106(11):3215-3221. PubMed ID: 28625725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subvisible Particles in IVIg Formulations Activate Complement in Human Serum.
    Chisholm CF; Behnke W; Pokhilchuk Y; Frazer-Abel AA; Randolph TW
    J Pharm Sci; 2020 Jan; 109(1):558-565. PubMed ID: 31672401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calculating the mass of subvisible protein particles with improved accuracy using microflow imaging data.
    Kalonia C; Kumru OS; Prajapati I; Mathaes R; Engert J; Zhou S; Middaugh CR; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):536-47. PubMed ID: 25302696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Differentiation of Protein Aggregates From Other Subvisible Particles in Viscous Mixtures Through Holographic Characterization.
    Winters A; Cheong FC; Odete MA; Lumer J; Ruffner DB; Mishra KI; Grier DG; Philips LA
    J Pharm Sci; 2020 Aug; 109(8):2405-2412. PubMed ID: 32439328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.
    Narhi LO; Corvari V; Ripple DC; Afonina N; Cecchini I; Defelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Spitznagel TM; Weiskopf A; Wuchner K
    J Pharm Sci; 2015 Jun; 104(6):1899-1908. PubMed ID: 25832583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of Infrared Microscopy to Assess Secondary Structure of Insulin Molecules Within Individual Subvisible Particles in Aqueous Formulations.
    Schack MM; Møller EH; Friderichsen AV; Carpenter JF; Rades T; Groenning M
    J Pharm Sci; 2019 Mar; 108(3):1117-1129. PubMed ID: 30773199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
    Nishi H; Mathäs R; Fürst R; Winter G
    J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of Stress-Induced Aggregate Size Distributions and Morphological Changes of a Bi-Specific Antibody Using Orthogonal Techniques.
    Hamrang Z; Hussain M; Tingey K; Tracka M; Casas-Finet JR; Uddin S; van der Walle CF; Pluen A
    J Pharm Sci; 2015 Aug; 104(8):2473-81. PubMed ID: 26053418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.
    Werk T; Volkin DB; Mahler HC
    Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Flow Imaging Analysis for Subvisible Particle Characterization in Glatiramer Acetate.
    Levin I; Zigman S; Komlosh A; Kettenring J
    J Pharm Sci; 2015 Nov; 104(11):3977-3983. PubMed ID: 26099719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium.
    Kiyoshi M; Shibata H; Harazono A; Torisu T; Maruno T; Akimaru M; Asano Y; Hirokawa M; Ikemoto K; Itakura Y; Iwura T; Kikitsu A; Kumagai T; Mori N; Murase H; Nishimura H; Oda A; Ogawa T; Ojima T; Okabe S; Saito S; Saitoh S; Suetomo H; Takegami K; Takeuchi M; Yasukawa H; Uchiyama S; Ishii-Watabe A
    J Pharm Sci; 2019 Feb; 108(2):832-841. PubMed ID: 30121316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.